{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:54:57Z","timestamp":1792713297785,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,27]],"date-time":"2016-01-27T00:00:00Z","timestamp":1453852800000},"content-version":"vor","delay-in-days":544,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jmii.2013.03.005","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T06:46:25Z","timestamp":1369896385000},"page":"268-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: From bench to bedside"],"prefix":"10.1016","volume":"47","author":[{"given":"Xi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2013.03.005_bib1","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jmii.2013.03.005_bib2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jmii.2013.03.005_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jmii.2013.03.005_bib4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jmii.2013.03.005_bib5","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jmii.2013.03.005_bib6","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","author":"Jensen","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jmii.2013.03.005_bib7","first-page":"879","article-title":"Identification and management of latent tuberculosis infection","volume":"79","author":"Hauck","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jmii.2013.03.005_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00126334-200001010-00010","article-title":"Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis","volume":"23","author":"Wood","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jmii.2013.03.005_bib9","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archinte.1997.00440280129013","article-title":"Association of tuberculosis risk with the degree of tuberculin reaction in HIV-infected patients. The Gruppo Italiano di Studio Tubercolosi e AIDS","volume":"157","author":"Girardi","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jama.1995.03530020061033","article-title":"Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA)","volume":"274","author":"Antonucci","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2013.03.005_bib11","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1093\/ndt\/gfr156","article-title":"Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years","volume":"26","author":"Canet","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jmii.2013.03.005_bib12","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/599035","article-title":"Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort","volume":"48","author":"Torre-Cisneros","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1183\/09031936.00201609","article-title":"Tuberculosis contact investigation in low prevalence countries: a European consensus","volume":"36","author":"Erkens","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2013.03.005_bib14","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib15","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmii.2013.03.005_bib16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1097-0142(197403)33:3<850::AID-CNCR2820330334>3.0.CO;2-H","article-title":"Tuberculosis complicating neoplastic disease. A review of 201 cases","volume":"33","author":"Kaplan","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.jmii.2013.03.005_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0962-8479(95)90529-4","article-title":"Incidence of pulmonary tuberculosis among diabetics","volume":"76","author":"Kim","year":"1995","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib19","first-page":"1049","article-title":"Tobacco and tuberculosis: a qualitative systematic review and meta-analysis","volume":"11","author":"Slama","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2458-8-289","article-title":"Alcohol use as a risk factor for tuberculosis - a systematic review","volume":"8","author":"Lonnroth","year":"2008","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jmii.2013.03.005_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1189\/jlb.0709517","article-title":"Infections and autoimmunity: the multifaceted relationship","volume":"87","author":"Sfriso","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jmii.2013.03.005_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement","volume":"36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2013.03.005_bib23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/rheumatology\/ker146","article-title":"The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jmii.2013.03.005_bib24","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jmii.2013.03.005_bib25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib26","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2005.09.007","article-title":"Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience","volume":"27","author":"Langley","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.jmii.2013.03.005_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.bmt.1705762","article-title":"Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease","volume":"40","author":"Perales","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jmii.2013.03.005_bib28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/art.23285","article-title":"Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade","volume":"58","author":"Wallis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jmii.2013.03.005_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib30","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3899\/jrheum.100623","article-title":"Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmii.2013.03.005_bib31","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1165\/rcmb.2009-0276TR","article-title":"Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease","volume":"43","author":"Chan","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jmii.2013.03.005_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1164\/rccm.200912-1862OC","article-title":"CD4 and CD8 T-cell responses to mycobacterial antigens in African children","volume":"182","author":"Tena-Coki","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib33","first-page":"1888","article-title":"Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections","volume":"31","author":"Beenhouwer","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmii.2013.03.005_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jmii.2013.03.005_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib36","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/517519","article-title":"Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis","volume":"195","author":"Plessner","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib37","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/IAI.01011-07","article-title":"Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs","volume":"76","author":"Chakravarty","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.jmii.2013.03.005_bib38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.27271","article-title":"Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model","volume":"62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jmii.2013.03.005_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3346\/jkms.2007.22.5.779","article-title":"Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea","volume":"22","author":"Yun","year":"2007","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jmii.2013.03.005_bib41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jmii.2013.03.005_bib42","first-page":"980","article-title":"Recommendations about prevention and management of tuberculosis before infliximab treatment","volume":"48","year":"2009","journal-title":"Chin J Intern Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib43","first-page":"546","article-title":"Recommendations about TNF-\u03b1 antagonist etanercept treatment of rheumatoid arthritis and ankylosing spondylitis","volume":"49","year":"2010","journal-title":"Chin J Intern Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1258\/ebm.2010.010278","article-title":"Revival of the identification of cytotoxic T-lymphocyte epitopes for immunological diagnosis, therapy and vaccine development","volume":"236","author":"Liu","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jmii.2013.03.005_bib45","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","article-title":"Comparative genomics of BCG vaccines by whole-genome DNA microarray","volume":"284","author":"Behr","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jmii.2013.03.005_bib46","doi-asserted-by":"crossref","first-page":"e12365","DOI":"10.1371\/journal.pone.0012365","article-title":"Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort","volume":"5","author":"Sutherland","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2013.03.005_bib47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2169\/internalmedicine.48.1432","article-title":"Clinical evaluation of the T-SPOT.TB test for patients with indeterminate results on the QuantiFERON TB-2G test","volume":"48","author":"Kobashi","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/thx.2009.126771","article-title":"Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios","volume":"65","author":"Chang","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jmii.2013.03.005_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1183\/09031936.06.00016906","article-title":"Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection","volume":"28","author":"Lee","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jmii.2013.03.005_bib50","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2172-10-31","article-title":"High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area","volume":"10","author":"Jiang","year":"2009","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jmii.2013.03.005_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.diagmicrobio.2010.12.020","article-title":"Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-gamma release assay in patients considered for anti-tumor necrosis factor-alpha therapy","volume":"71","author":"Casas","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"59","key":"10.1016\/j.jmii.2013.03.005_bib53","first-page":"1","article-title":"Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States","volume":"2010","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jmii.2013.03.005_bib54","series-title":"Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control","year":"2006"},{"key":"10.1016\/j.jmii.2013.03.005_bib55","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s10067-011-1771-9","article-title":"Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea","volume":"30","author":"Chang","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jmii.2013.03.005_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.200811-1704OC","article-title":"Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing","volume":"180","author":"van Zyl-Smit","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib57","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1164\/rccm.201001-0083OC","article-title":"Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans","volume":"182","author":"Place","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jmii.2013.03.005_bib58","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09247","article-title":"An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis","volume":"466","author":"Berry","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2013.03.005_bib59","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3899\/jrheum.081041","article-title":"Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jmii.2013.03.005_bib60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jmii.2013.03.005_bib61","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite\u00a0chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411821300039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S168411821300039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:18:33Z","timestamp":1761657513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S168411821300039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S168411821300039X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2013.03.005","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2013.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}